Monday, April 24, 2017 4:06:49 PM
Scientific and Clinical Advisory Board
Taylor Schreiber, M.D., Ph.D.
Chairman
As Heat Biologics’ former Chief Scientific Officer, Dr. Schreiber is co-inventor of significant elements of the company’s ImPACT and ComPACT immunotherapy platforms. He most recently joined Shattuck Labs, Inc., a biotechnology company focused on developing technology exclusively licensed from Heat, as their Chief Scientific Officer. Taylor was also a scientific founder of Pelican Therapeutics, which developed a first-in-class agonist antibody to human TNFRSF25. As a cancer biologist and drug development scientist, Dr. Schreiber possesses over 15 years of laboratory experience in the discovery of novel therapeutic immuno-oncology compounds. Dr. Schreiber received his Ph.D. from the Sheila and David Fuente Program in cancer biology as well as his M.D. at the University of Miami Miller School of Medicine. In addition, he completed his post-doctoral fellowship with the original inventor of Heat’s ImPACT technology platform, Eckhard R. Podack, M.D., Ph.D., studying the immunobiology of TNFRSF25. Dr. Schreiber has authored over 30 peer-reviewed tumor immunology and heat shock protein-based cancer immunotherapy publications.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/07/2024 04:15:18 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM